Paratek Pharmaceuticals (PRTK) Shareholder Roumell Asset Management Has Lifted Its Position by $1.26 Million; Chemical Bank Boosted Its Position in Aflac (AFL) as Stock Value Declined

June 16, 2018 - By Hazel Jackson

Aflac Incorporated (NYSE:AFL) Logo

Jim Roumell increased its stake in Paratek Pharmaceuticals Inc (PRTK) by 96.02% based on its latest 2018Q1 regulatory filing with the SEC. Roumell Asset Management Llc bought 96,668 shares as the company’s stock declined 24.82% with the market. The hedge fund run by Jim Roumell held 197,347 shares of the health care company at the end of 2018Q1, valued at $2.57 million, up from 100,679 at the end of the previous reported quarter. Roumell Asset Management Llc who had been investing in Paratek Pharmaceuticals Inc for a number of months, seems to be bullish on the $349.14M market cap company. The stock increased 1.84% or $0.2 during the last trading session, reaching $11.05. About 427,881 shares traded. Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has declined 50.36% since June 16, 2017 and is downtrending. It has underperformed by 62.93% the S&P500. Some Historical PRTK News: 04/04/2018 – PARATEK: FDA ACCEPTED NDA W/ PRIORITY REVIEW FOR OMADACYCLINE; 23/04/2018 – PARATEK ON TRACK TO FILE MAA IN EU IN 2H; 04/04/2018 – Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA; 12/04/2018 – Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018; 23/04/2018 – PARATEK REPORTS EFFICACY DATA OF ORAL-ONLY OMADACYCLINE; 15/05/2018 – Armistice Capital Buys New 1.8% Position in Paratek; 04/04/2018 – PARATEK’S NEW DRUG APPLICATIONS FOR ORAL AND INTRAVENOUS OMADACYCLINE ACCEPTED FOR PRIORITY REVIEW BY FDA; 23/04/2018 – PARATEK SAYS OMADACYCLINE `EFFECTIVE’ IN OASIS-2 PHASE 3 STUDY; 28/03/2018 – Paratek at HC Wainwright Global Biotechnology Conference Apr 9; 23/04/2018 – Paratek Pharmaceuticals On Track to File Marketing Authorization Applications in the European Union in the 2H

Chemical Bank increased its stake in Aflac Inc (AFL) by 96.46% based on its latest 2018Q1 regulatory filing with the SEC. Chemical Bank bought 14,291 shares as the company’s stock declined 0.09% with the market. The institutional investor held 29,106 shares of the accident &health insurance company at the end of 2018Q1, valued at $1.27 million, up from 14,815 at the end of the previous reported quarter. Chemical Bank who had been investing in Aflac Inc for a number of months, seems to be bullish on the $35.42 billion market cap company. The stock increased 0.15% or $0.07 during the last trading session, reaching $45.75. About 4.43M shares traded or 28.47% up from the average. Aflac Incorporated (NYSE:AFL) has risen 21.38% since June 16, 2017 and is uptrending. It has outperformed by 8.81% the S&P500. Some Historical AFL News: 03/04/2018 – AFLAC NAMES J. TODD DANIELS AS EVP; PRINCIPAL FINL OFFICER; 25/04/2018 – Aflac 1Q Adj EPS $1.05; 25/04/2018 – AFLAC 1Q ADJ. EPS EX-YEN IMPACT $1.02; 04/04/2018 – Aflac Recognized for Social Responsibility; 17/04/2018 – Country Music Star Chris Young Joins Aflac to Present First-Ever Aflac ACM Lifting Lives Honor for Excellence in Music Therapy; 02/04/2018 – AFLAC AFFIRMED BY FITCH, OUTLOOK STABLE; 25/04/2018 – Aflac 1Q EPS 91c; 03/04/2018 – Aflac Names J. Todd Daniels as EVP; Principal Financial Officer, Aflac Japan and Albert A. Riggieri as SVP, Global Chief Risk Officer and Chief Actuary, Aflac Incorporated; 31/05/2018 – MEDIA-SEC is said to review allegations that Aflac misled investors – Bloomberg; 03/04/2018 – Aflac Names J. Todd Daniels as EVP; Principal Financial Officer, Aflac Japan and Albert A. Riggieri as SVP, Global Chief Risk O

Among 10 analysts covering Paratek Pharmaceuticals (NASDAQ:PRTK), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Paratek Pharmaceuticals had 27 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Tuesday, April 4 by Wedbush. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has “Buy” rating given on Thursday, September 21 by Robert W. Baird. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has “Buy” rating given on Tuesday, July 18 by Leerink Swann. Gabelli initiated the shares of PRTK in report on Thursday, July 23 with “Buy” rating. The firm has “Buy” rating given on Friday, June 17 by H.C. Wainwright. The stock has “Outperform” rating by Raymond James on Friday, March 2. As per Friday, May 13, the company rating was initiated by Robert W. Baird. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) earned “Hold” rating by Zacks on Saturday, August 22. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) earned “Buy” rating by Cantor Fitzgerald on Monday, July 17. On Thursday, March 1 the stock rating was maintained by Cantor Fitzgerald with “Buy”.

Investors sentiment increased to 2.31 in 2018 Q1. Its up 1.40, from 0.91 in 2017Q4. It improved, as 16 investors sold PRTK shares while 13 reduced holdings. 22 funds opened positions while 45 raised stakes. 20.55 million shares or 6.29% more from 19.34 million shares in 2017Q4 were reported. Morgan Stanley accumulated 0% or 205,933 shares. Voya Inv Mgmt Ltd Liability holds 0% or 10,573 shares. Metropolitan Life Ins holds 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) or 8,135 shares. Baupost Gru Limited Liability Ma invested in 0.3% or 2.39 million shares. 1,029 were reported by Royal National Bank & Trust Of Canada. Price T Rowe Associate Md reported 10,212 shares stake. Susquehanna International Grp Inc Llp has 60,865 shares for 0% of their portfolio. Moreover, Omni Partners Limited Liability Partnership has 0.28% invested in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) for 154,564 shares. Daiwa holds 0% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) for 173 shares. California Public Employees Retirement Systems holds 0% or 120,400 shares in its portfolio. Boston Prns stated it has 0% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Community Commercial Bank Na stated it has 500 shares. American Intl Grp Inc has invested 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Cadence Ltd Liability has invested 0.06% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Rhumbline Advisers has invested 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK).

More notable recent Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) news were published by: Nasdaq.com which released: “Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Data at ASM Microbe 2018” on June 07, 2018, also Prnewswire.com with their article: “Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018” published on June 06, 2018, Streetinsider.com published: “Paratek Pharmaceuticals (PRTK) Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting …” on June 11, 2018. More interesting news about Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) were released by: Nasdaq.com and their article: “Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline …” published on June 11, 2018 as well as Seekingalpha.com‘s news article titled: “Integrated BioSci Research On Cidara Therapeutics: What’s In Store For This Promising Antibiotic Innovator?” with publication date: June 08, 2018.

Roumell Asset Management Llc, which manages about $293.14M and $45.42M US Long portfolio, decreased its stake in Liquidity Services Inc (NASDAQ:LQDT) by 219,900 shares to 888,328 shares, valued at $5.77 million in 2018Q1, according to the filing.

Among 22 analysts covering Aflac Incorporated (NYSE:AFL), 5 have Buy rating, 2 Sell and 15 Hold. Therefore 23% are positive. Aflac Incorporated had 60 analyst reports since August 12, 2015 according to SRatingsIntel. Bank of America upgraded Aflac Incorporated (NYSE:AFL) on Thursday, April 6 to “Neutral” rating. The stock has “Hold” rating by Wells Fargo on Tuesday, January 9. The firm earned “Hold” rating on Friday, December 11 by Sandler O’Neill. The company was upgraded on Thursday, September 10 by Citigroup. The stock of Aflac Incorporated (NYSE:AFL) has “Neutral” rating given on Thursday, January 26 by Citigroup. The stock of Aflac Incorporated (NYSE:AFL) earned “Hold” rating by Sandler O’Neill on Monday, May 23. On Thursday, February 1 the stock rating was maintained by SunTrust with “Hold”. The firm has “Sell” rating by RBC Capital Markets given on Monday, October 9. The firm has “Sector Perform” rating by RBC Capital Markets given on Tuesday, February 2. As per Tuesday, September 5, the company rating was maintained by RBC Capital Markets.

Chemical Bank, which manages about $915.12 million US Long portfolio, decreased its stake in Exxonmobil Corp (NYSE:XOM) by 22,387 shares to 151,483 shares, valued at $11.30 million in 2018Q1, according to the filing. It also reduced its holding in Align Technology Inc (NASDAQ:ALGN) by 2,054 shares in the quarter, leaving it with 1,831 shares, and cut its stake in Vanguard Dividend Apprec Etf (VIG).

Since February 16, 2018, it had 2 buys, and 4 insider sales for $2.81 million activity. Shares for $178,090 were bought by Lloyd Karole on Tuesday, February 20. HOWARD JUNE P sold $239,194 worth of stock. AMOS DANIEL P sold $2.24 million worth of stock. KNAPP CHARLES B had sold 10,000 shares worth $437,155. $49,022 worth of Aflac Incorporated (NYSE:AFL) shares were bought by MOSKOWITZ JOSEPH L.

Aflac Incorporated (NYSE:AFL) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>